Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (NASDAQ: PAVM) generates news across medical devices, diagnostics, and digital health, reflecting its role as a diversified, commercial-stage medical technology company. Its news flow often covers developments at the parent company level as well as at its subsidiaries, Lucid Diagnostics Inc. and Veris Health Inc., which focus on cancer prevention diagnostics and digital cancer care.
Investors following PAVM news can expect updates on corporate actions, such as the announced 1-for-30 reverse stock split intended to help the company meet Nasdaq’s minimum bid price requirement and maintain its listing on the Nasdaq Capital Market. Company communications also highlight business updates, quarterly financial results, and information on balance sheet and capital structure decisions, often furnished through press releases and Form 8-K filings.
News related to Lucid Diagnostics, a subsidiary of PAVmed, frequently focuses on the commercialization and clinical performance of the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Recent announcements have described large real-world datasets on non-endoscopic esophageal precancer detection, Medicare coverage processes, and participation in medical and investor conferences.
Updates involving Veris Health typically center on the Veris Cancer Care Platform and its deployment in clinical settings. For example, PAVmed and Veris have reported the launch of the commercial phase of a long-term strategic partnership with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, focused on enhancing personalized cancer care for patients undergoing systemic cancer therapy.
This PAVM news page brings together these types of announcements, allowing readers to track financial disclosures, technology and platform milestones, regulatory and reimbursement developments, strategic partnerships, and corporate governance actions over time.
PAVmed Inc. (Nasdaq: PAVM) announced that Stanley Lapidus, a pioneer in medical diagnostics, has joined its subsidiary Lucid Diagnostics as a Strategic Advisor. His experience in early cancer detection is expected to enhance the commercialization of Lucid's EsoGuard and EsoCheck technologies. EsoGuard aims to significantly improve the diagnosis of Barrett’s Esophagus and esophageal cancer. Lapidus brings over 30 years of expertise, having led companies like Exact Sciences and Cytyc. This collaboration aims to expedite Lucid's clinical trials and regulatory strategies.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced that its subsidiary, Lucid Diagnostics, received a preliminary payment determination for the EsoGuard™ Esophageal DNA Test. The U.S. CMS indicated a recommended payment of $1,938.01 in 38 states and $2,690 in 12 states for EsoGuard, effective from January 1, 2021, through December 31, 2023. This noninvasive test aids in diagnosing Barrett’s Esophagus, a precursor to esophageal cancer. The payment determination is open for public comments until August 10, 2020, with finalization to follow.
PAVmed Inc. (Nasdaq: PAVM) announced a letter of intent with Canon Virginia to manufacture molded resorbable pediatric ear tubes using aqueous silk fibroin. This collaboration aims to develop commercial-grade processes for the DisappEAR tubes, expected to revolutionize treatment for children undergoing ear tube placement, a common surgery in the U.S. Canon's advanced manufacturing capabilities will support efficient production, ultimately benefiting up to one million affected children annually.
PAVmed Inc. (PAVM) reported preliminary financial results for Q1 2020, revealing a GAAP net loss of approximately $14.5 million, or $(0.33) per share, with non-GAAP adjusted loss of $4.5 million, or $(0.10) per share. The company secured FDA marketing clearance for its CarpX™ device and initiated clinical trials for its EsoGuard™/EsoCheck™ diagnostics. Despite challenges from the Covid-19 pandemic, PAVmed's activities remain on track with key developments in its product lineup and ongoing trials, alongside an increase in cash reserves to $8.7 million as of March 31, 2020.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will hold a business update conference call on May 21, 2020, at 4:30 PM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's Q1 2020 financial results and upcoming milestones. PAVmed is known for its innovative medical device solutions across various fields, including GI health and minimally invasive interventions. The company leverages a unique business model for rapid product commercialization. Live access to the call is available via phone or webcast on its investor relations website.